Ph.D., Vice President of Medical Affairs, Mitra Biotech
Dr Ehrhardt currently serves as the head of Global Medical Affairs for Mitra Biotech, leading the
company’s investigator- and company-sponsored clinical research programs, as well as other
Medical Affairs functions. Prior to joining Mitra, Dr. Ehrhardt held Medical Affairs leadership
roles in the oncology and infectious diseases therapeutic areas with Onyx Pharmaceuticals
(Amgen), Sanofi, Millennium Pharmaceuticals, Cubist Pharmaceuticals, and Bristol-Myers
Squibb. Dr. Ehrhardt served as President of the Investigator Initiated Sponsored Research
Association (IISRA) during its integration into the Association of Clinical Research Professionals
(ACRP). Prior to joining industry, Dr. Ehrhardt was on the faculty of Creighton University’s
School of Medicine.
Immunotherapy Showcase: Mitra Biotech
Mitra Biotech’s CANscript™ is an ex-vivo translational platform that delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to support more effective and efficient oncology drug development decision making and to inform patient-specific cancer therapeutic selection.